SlidesetHIVViral Hepatitis and Liver DiseaseClinical Development of Long-Acting Broadly Neutralizing Monoclonal Antibodies: Lessons Learned Thus Far- Richard Koup, MDView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseViral Dynamics and the Search for an HIV Cure - Stephen Becker, MDView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseThe use of DAA’s in pregnancy in HCV infected mothers- David Burger, PharmD, PhDView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseClinical case presentation- David Thomas, MD, PhDView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseTenofovir exposure during pregnancy and postpartum in hepatitis B mono-infected women on TDF monotherapy compared to HIV-infected women on TDF-containing antiretroviral therapy- Tim Cressey, PhDView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseIntracellular 007-TP Concentrations are Associated with Gradients of Adherence to Ledipasvir/Sofosbuvir- Leah JimmersonView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseA Pharmacometabolomics Approach for Predicting Tenofovir diphosphate (TFV-DP) Concentrations in Dried Blood Spots (DBS)- Mustafa IbrahimView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseApplication of Physiologically based pharmacokinetic (PBPK) Modelling to Drug Development Decisions- Joga Gobburu, PhD, MBAView Slideset
SlidesetHIVViral Hepatitis and Liver DiseasePhysiologically based pharmacokinetic modeling and simulation in drug product development and review - Xinyuan Zhang, PhDView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseHow/when will pharmacogenomics translate into improved clinical care?- David Haas, MDView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseLast advances in HIV pharmacogenomics - Andrea Calcagno, MD, DTM&HView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseSLC22a2 genetic variants and dolutegravir trough concentrations correlate with specific psychiatric symptoms in hiv-positive patients on dolutegravir- Alberto BorghettiView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseAge, Inflammation, Blood Brain Barrier Permeability and Single Nucleotide Polymorphisms in Transporters May Influence Cerebrospinal Fluid Antiretrovirals' Concentrations- Andrea Calcagno, MD, DTM&HView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseAssessment of maternal and fetal dolutegravir exposure by integrating ex vivo placental perfusion data and physiologically-based pharmacokinetic modeling- Jolien FreriksenView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseDoes hepatic impairment affect the exposure of monoclonal antibodies? - Qin SunView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseReduced nevirapine concentrations among HIV-positive women receiving mefloquine for intermittent preventive treatment for malaria control during pregnancy- HaalandView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseElvitegravir pharmacokinetics during Pregnancy and Postpartum- Angela ColbersView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseClinical Pharmacology of Integrase Inhibitors - Giovanni Di Perri, MD, PhDView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseClinical case presentation - Marta Boffito, MD, PhD, FRCPView Slideset
SlidesetHIVViral Hepatitis and Liver DiseasePharmacokinetic and virological efficacy of dolutegravir (50 mg BID) containing regimen in association with rifampin in HIV-infected patients using Dried Blood Spot: ANRS-12313 NAMSAL sub-study in Cameroon- LeView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseFirst report of dolutegravir unbound plasma concentrations during pregnancy in HIV-positive women- Pauline BollenView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseUpdate on DDI guidelines of the FDA - in vitro- Xinning Yang, PhDView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseUpdate on DDI guidelines of the FDA - in vivo- Kellie Reynolds, PharmDView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseHow to End the Global HCV Epidemic - the role of injectables- David Thomas, MD, PhDView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseMedication safety issues associated with currently used first-line antiretroviral regimens in Uganda- Kay SedenView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseIntraindividual comparison of efavirenz, atazanavir, or ritonavir plasma pharmacokinetics before and during 21-days of vaginally administered hormone contraception- Kimberly Scarsi, PharmD, MS, FCCPView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseRifabutin (RBT) Decreases Cabotegravir (CAB) Exposure following Oral Co-administration- PatelView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseRifabutin PK and Safety among HIV/TB Coinfected Children Receiving Lopinavir- Holly RawizzaView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseClinical Pharmacology of HIV Pre-Exposure Prophylaxis (PrEP) – Where are we now?- Craig HendrixView Slideset
SlidesetHIVViral Hepatitis and Liver DiseasePopulation Pharmacokinetics and Pharmacokinetics/Pharmacodynamics of Etravirine in HIV-positive Children Ages 1-<6 Years- Mustafa IBrahimView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseDifferential brain tissue penetration of antiretrovirals and fluconazole- Katelyn PastickView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseComparison of 5 online free access expert databases to check drug-drug interactions between antiretroviral drugs and co-prescribed medications from a French cohort of HIV-infected outpatients - LeView Slideset
